636 related articles for article (PubMed ID: 17877113)
1. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.
Dejica DI; Manea EM
Roum Arch Microbiol Immunol; 2006; 65(1-2):66-74. PubMed ID: 17877113
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells.
Devi BS; Van Noordin S; Krausz T; Davies KA
J Autoimmun; 1998 Oct; 11(5):471-5. PubMed ID: 9802931
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of CD23 hyperexpression on B cells from patients with rheumatoid arthritis.
De Miguel S; Galocha B; Jover JA; Bañares A; Hernández-García C; García-Asenjo JA; Fernández-Gutiérrez B
J Rheumatol; 2001 Jun; 28(6):1222-8. PubMed ID: 11409113
[TBL] [Abstract][Full Text] [Related]
4. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus.
Grammer AC; Lipsky PE
Arthritis Rheum; 2002 Jun; 46(6):1417-29. PubMed ID: 12115170
[No Abstract] [Full Text] [Related]
5. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.
Toubi E; Shoenfeld Y
Autoimmunity; 2004; 37(6-7):457-64. PubMed ID: 15621572
[TBL] [Abstract][Full Text] [Related]
6. IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus.
Díaz-Alderete A; Crispin JC; Vargas-Rojas MI; Alcocer-Varela J
J Autoimmun; 2004 Dec; 23(4):379-83. PubMed ID: 15571932
[TBL] [Abstract][Full Text] [Related]
7. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.
Grammer AC; Slota R; Fischer R; Gur H; Girschick H; Yarboro C; Illei GG; Lipsky PE
J Clin Invest; 2003 Nov; 112(10):1506-20. PubMed ID: 14617752
[TBL] [Abstract][Full Text] [Related]
8. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
9. Regulatory B cells in autoimmune diseases: how do they work?
Lemoine S; Morva A; Youinou P; Jamin C
Ann N Y Acad Sci; 2009 Sep; 1173():260-7. PubMed ID: 19758160
[TBL] [Abstract][Full Text] [Related]
10. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus.
Wang X; Huang W; Schiffer LE; Mihara M; Akkerman A; Hiromatsu K; Davidson A
Arthritis Rheum; 2003 Feb; 48(2):495-506. PubMed ID: 12571860
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the number of CD154 molecules in membrane extracts used as a source of CD40 stimulation of human B lymphocytes.
Ducas E; Dussault N; Roy A; Dumont N; Néron S
J Immunol Methods; 2009 May; 344(2):133-7. PubMed ID: 19332074
[TBL] [Abstract][Full Text] [Related]
12. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro.
Néron S; Boire G; Dussault N; Racine C; de Brum-Fernandes AJ; Côté S; Jacques A
Arch Immunol Ther Exp (Warsz); 2009; 57(6):447-58. PubMed ID: 19866343
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic CD154 antibody for lupus: promise for the future?
Kelsoe G
J Clin Invest; 2003 Nov; 112(10):1480-2. PubMed ID: 14617748
[TBL] [Abstract][Full Text] [Related]
14. CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis.
Alaaeddine N; Hassan GS; Yacoub D; Mourad W
Clin Dev Immunol; 2012; 2012():490148. PubMed ID: 22110533
[TBL] [Abstract][Full Text] [Related]
15. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates.
Gong YF; Xiang LX; Shao JZ
J Immunol; 2009 Jun; 182(12):7749-62. PubMed ID: 19494299
[TBL] [Abstract][Full Text] [Related]
16. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis.
Munroe ME
Semin Immunol; 2009 Oct; 21(5):283-8. PubMed ID: 19539498
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
[TBL] [Abstract][Full Text] [Related]
18. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
Batrla R; Linnebacher M; Rudy W; Stumm S; Wallwiener D; Gückel B
Cancer Res; 2002 Apr; 62(7):2052-7. PubMed ID: 11929824
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.
Howard LM; Miller SD
Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus.
Katsiari CG; Liossis SN; Souliotis VL; Dimopoulos AM; Manoussakis MN; Sfikakis PP
Clin Immunol; 2002 Apr; 103(1):54-62. PubMed ID: 11987985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
